Referencing for people who value simplicity, privacy, and speed.Get Citationsy
← Back to Search
Localization Of 1,25-dihydroxyvitamin D3 Receptor (VDR) Expression In Human Prostate
M. Kivineva, M. Bläuer, H. Syvälä, T. Tammela, P. Tuohimaa
Published 1998 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) has been found to have a variety of physiological functions, including effects on growth and differentiation in normal and malignant cells. The antiproliferative effects of 1,25(OH)2D3 are reported to be mediated through the genomic signaling pathway by binding to a specific high affinity receptor protein, the 1,25-dihydroxyvitamin D3 receptor (VDR). VDR has been localized in a variety of tissues, but little is known about VDR distribution in human prostate. In this study, we raised an antibody against a synthetic peptide corresponding to amino acids 10-24 of human vitamin D receptor. The sequence selected for immunization is identical in human, rat and mouse VDR. Based on this antibody, we developed an immunohistochemical method suitable for studying VDR expression in paraffin-embedded tissue. The immunohistochemical staining was verified using classical target organs for vitamin D (kidney, intestine, skin). With this method, we studied VDR localization on paraffin-embedded human prostatic tissue obtained from 8 patients undergoing radical prostatectomy for urinary bladder cancer and demonstrate VDR expression in the secretory epithelial and few stromal cells of human prostate. The nuclear staining in the secretory epithelial cells was concentrated near the nuclear membrane and in discrete foci in the nucleoplasm. This suggests that effects of 1,25-dihydroxyvitamin D3 are mediated through VDR in these cells. Moreover our result indicates that there are strong variations in VDR expression between prostatic samples.
This paper references
Homologous up-regulation of the 1,25 (OH)2 vitamin D3 receptor in rats.
E. Costa (1986)
1,25-Dihydroxyvitamin D3 and the Regulation of Human Cancer Cell Replication 1
J. Eisman (1989)
Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney.
R. Kumar (1994)
Prostatic adenocarcinoma of ductal origin
V. Dube (1973)
Immunocytology with microwave-fixed fibroblasts shows 1 alpha,25- dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors
J. Barsony (1990)
Prostate androgen receptor: immunohistological localization and mRNA characterization.
C. Chang (1989)
Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry
H. Schulze (1990)
Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.
S. Ingles (1997)
Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription.
P. Yen (1997)
Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells.
T. Hsieh (1996)
Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues
U. Berger (1988)
Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections
G. Cattoretti (1993)
Distribution of soltriol [1,25(OH)2-vitamin D3] binding sites in male sex organs of the mouse: an autoradiographic study.
G. Schleicher (1989)
Multiple sclerosis and prostate cancer: what do their similar geographies suggest?
G. Schwartz (1992)
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
Schwartz Gg (1990)
Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin.
P. Milde (1991)
Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation
C. L. Hanchette (1992)
Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3.
S. Christakos (1996)
Newly identified actions of the vitamin D endocrine system.
M. R. Walters (1992)
Induction of transforming growth factor‐β autocrine activity by all‐trans‐retinoic acid and 1α,25‐dihydroxyvitamin D3 in NRP‐152 rat prostatic epithelial cells
D. Danielpour (1996)
Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin D receptor.
R. Horst (1990)
Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
S-H Zhuang (1997)
Protein measurement with the Folin phenol reagent.
O. H. Lowry (1951)
The cellular transcription factor CREB corresponds to activating transcription factor 47 (ATF-47) and forms complexes with a group of polypeptides related to ATF-43.
H. Hurst (1990)
Monocytic Differentiation of Acute Promyelocytic Leukemia Cells in Response to 1,25-Dihydroxyvitamin D3 Is Independent of Nuclear Receptor Binding (*)
M. Bhatia (1995)
Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
T. Hedlund (1996)
Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy.
N. Konishi (1993)
The role of vitamin D in normal prostate growth and differentiation.
B. Konety (1996)
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
E. Corder (1993)
Steroid hormone modulation of vitamin D receptor levels in human MG-63 osteosarcoma cells.
A. Mahonen (1994)
Immunohistochemical localization of progesterone receptor in benign and malignant human prostate
B. Mobbs (1990)
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
R. Skowroński (1993)
Subcellular Distribution of Normal and Mutant Vitamin D Receptors in Living Cells
J. Barsony (1997)
Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women.
P. Ebeling (1992)
Antipeptide antibodies to two distinct regions of the androgen receptor localize the receptor protein to the nuclei of target cells in the rat and human prostate.
D. Husmann (1990)
Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms.
D. Saunders (1992)
Cloning and expression of full-length cDNA encoding human vitamin D receptor.
A. R. Baker (1988)
Glucocorticoid regulation of 1,25(OH)2vitamin D3 receptors: divergent effects on mouse and rat intestine.
M. Hirst (1982)
Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells
M. T. F. Escaleira (1993)
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
D. Peehl (1994)
1α, 25‐Dihydroxyvitamin D3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line
Renny T. Franceschi (1985)
This paper is referenced by
The role of Vitamin D3 metabolism in prostate cancer
Y. Lou (2004)
Adjuvant Action of Hepatocyte Growth Factor in Vitamin D Therapy of Androgen-Unresponsive Prostate Cancer
B. A. Roos (1999)
International Congress on Hormonal Steroids and Hormones and Cancer The role of vitamin D and retinoids in controlling prostate cancer progression
D. Peehl (2003)
Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)
M. Maggi (2006)
Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity
Peter E. Hutchinson (2018)
BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
E. Colli (2006)
Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.
C. Crescioli (2004)
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression
A. Krishnan (2003)
Nuclear receptor co-repressor actions in bladder cancer
S. Asad Abedin (2010)
Vitamin D Deficiency and the Epidemiology of Prostate Cancer
G. Schwartz (2010)
The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
C. Perez-Stable (2002)
Review of Potential Indicators of Adequacy and Selection of Indicators: Calcium and Vitamin D
A. Ross (2011)
Effects of 1,25‐dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells
E. Leman (2003)
CHAPTER 94 – Vitamin D and Prostate Cancer
A. Krishnan (2005)
Vitamin D and intervention trials in prostate cancer: from theory to therapy.
G. Schwartz (2009)
Vitamin D and cancer
R. Bouillon (2006)
The effects of regular tanning bed use and increased vitamin D status on bone mineral density and serum inflammatory markers in healthy women
M. Heffernan (2007)
Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status
S. Mordan-McCombs (2010)
Where is the vitamin D receptor?
Y. Wang (2012)
Sunlight, Vitamin D and Prostate Cancer Epidemiology
G. Schwartz (2011)
Links between genetic and environmental factors and prostate cancer risk
P. Ekman (1999)
Vitamin D and Prostate Cancer
S. Blutt (1999)
Prostate Diseases and the Metabolic Syndrome
M. Haghsheno (2015)
Associations between canine male reproductive parameters and serum Vitamin D and prolactin concentrations
A. Kukk (2011)
Low 25-OH vitamin D is associated with benign prostatic hyperplasia.
M. Haghsheno (2013)
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
M. Ahonen (2004)
Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by ligands
M. Ahonen (2000)
Dietary Carcinogens and DNA Adducts in Prostate Cancer.
Medjda Bellamri (2019)
The role of vitamin D and retinoids in controlling prostate cancer progression.
D. Peehl (2003)
Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention
L. Diaw (2007)
Vitamin D, vitamin D analogs (deltanoids) and prostate cancer
William M. Brown (2008)
Dietary Vitamin D and Vitamin D Receptor Level Modulate Epithelial Cell Proliferation and Apoptosis in the Prostate
P. Kovalenko (2011)See more